Novo Nordisk parent to buy Catalent for $16.5 billion to expand Wegovy supply
Publishing timestamp: 2024-02-05 10:52:46
Summary
Novo Nordisk's parent company, Novo Holdings, will acquire drug manufacturer Catalent in a $16.5 billion deal. This acquisition could help boost the supply of weight loss injection Wegovy and diabetes shot Ozempic. Catalent is the main supplier of fill-finish work for Novo Nordisk's Wegovy. Novo Nordisk will also buy three of Catalent's manufacturing sites from Novo Holdings for $11 billion. The deal is expected to close at the end of 2024, and Novo Nordisk expects it to increase its filling capacity starting in 2026.
Sentiment: NEUTRAL
Tickers: CTLT, NOVO.B-DK, LLY,
Keywords: breaking news, novo nordisk a/s, biotech and pharmaceuticals, diabetes, business news, catalent inc, weight management, pharmaceuticals, biotechnology, health care industry, business, eli lilly and co,
Source: https://www.cnbc.com/2024/02/05/novo-nordisk-parent-to-buy-catalent-to-expand-wegovy-supply.html